- Home
- TGHL vs CVKD Comparison
TGHL vs CVKD Comparison
Compare TGHL & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | CVKD |
|---|---|---|
| Founded | 2020 | 2022 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 9.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | TGHL | CVKD |
|---|---|---|
| Price | $0.40 | $5.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 29.5K | ★ 48.7K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $4.21 |
| 52 Week High | $3.80 | $17.50 |
Technical Indicators
Market Signals| Indicator | TGHL | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 50.82 |
| Support Level | $0.33 | $5.13 |
| Resistance Level | $0.38 | $8.87 |
| Average True Range (ATR) | 0.03 | 0.51 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 60.09 | 72.97 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.